Loading...
Please wait, while we are loading the content...
Similar Documents
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.
| Content Provider | Europe PMC |
|---|---|
| Author | Tallantyre, Emma C Scurr, Martin J Vickaryous, Nicola Richards, Aidan Anderson, Valerie Baker, David Chance, Randy Evangelou, Nikos George, Katila Giovannoni, Gavin Harding, Katharine E Hibbert, Aimee Ingram, Gillian Jolles, Stephen Jones, Meleri Kang, Angray S Loveless, Samantha Moat, Stuart J Robertson, Neil P Rios, Francesca Schmierer, Klaus Willis, Mark Godkin, Andrew Dobson, Ruth |
| Copyright Year | 2022 |
| Abstract | BackgroundPeople with MS treated with anti-CD20 therapies and fingolimod often have attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the benefit of a 3rd (booster) COVID-19 vaccine in this group.MethodsPwMS without a detectable IgG response following COVID-19 vaccines 1&2 were invited to participate. Participants provided a dried blood spot +/- venous blood sample 2–12 weeks following COVID-19 vaccine 3. Humoral and T cell responses to SARS-CoV-2 spike protein and nucleocapsid antigen were measured.ResultsOf 81 participants, 79 provided a dried blood spot sample, of whom 38 also provided a whole blood sample; 2 provided only whole blood. Anti-SARS-CoV-2-spike IgG seroconversion post-COVID-19 vaccine 3 occurred in 26/79 (33%) participants; 26/40 (65%) had positive T-cell responses. Overall, 31/40 (78%) demonstrated either humoral or cellular immune response post-COVID-19 vaccine 3. There was no association between laboratory evidence of prior COVID-19 and seroconversion following vaccine 3.ConclusionsApproximately one third of pwMS who were seronegative after initial COVID-19 vaccination seroconverted after booster (third) vaccination, supporting the use of boosters in this group. Almost 8 out of 10 had a measurable immune response following 3rd COVID-19 vaccine. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9166227&blobtype=pdf |
| ISSN | 22110348 |
| Journal | Multiple Sclerosis and Related Disorders [Mult Scler Relat Disord] |
| Volume Number | 64 |
| DOI | 10.1016/j.msard.2022.103937 |
| PubMed Central reference number | PMC9166227 |
| PubMed reference number | 35700625 |
| e-ISSN | 22110356 |
| Language | English |
| Publisher | The Authors. Published by Elsevier B.V. |
| Publisher Date | 2022-06-04 |
| Access Restriction | Open |
| Rights License | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. © 2022 The Authors. Published by Elsevier B.V. |
| Subject Keyword | Multiple sclerosis (MS) COVID-19 Vaccination Disease modifying therapies (DMTs) Immune response |
| Content Type | Text |
| Resource Type | Article |
| Subject | Neurology Neurology (clinical) |
